Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Wakamoto Pharmaceutical Co's Enterprise Value is 円8,042 Mil.
Wakamoto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円258 Mil. Therefore, Wakamoto Pharmaceutical Co's EV-to-EBIT ratio for today is 31.14.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Wakamoto Pharmaceutical Co (TSE:4512) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Wakamoto Pharmaceutical Co's EV-to-EBIT for today is
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Wakamoto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円258 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Wakamoto Pharmaceutical Co's EV-to-EBITDA for today is:
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Wakamoto Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円701 Mil.
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Wakamoto Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円9,907 Mil.
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Wakamoto Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 円-487 Mil.
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Wakamoto Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-1,141 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co Enterprise Value Related Terms
Wakamoto Pharmaceutical Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4512 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's Enterprise Value falls into.
Wakamoto Pharmaceutical Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Wakamoto Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a Enterprise Value of 円8,042 Mil as of Jul. 15, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Enterprise Value too high?
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Enterprise Value compare to ZTS and UTHR?
Wakamoto Pharmaceutical Co's Enterprise Value of 円8,042 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,042 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.14, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current Enterprise Value is 円8,042 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Enterprise Value is 円8,042 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.14.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
Enterprise Value: 円8,042 Mil
GF Value™: 円319.14 vs. price of 円278.00 (12.9% below fair value)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
